Market Analysis - Diabetes Global 2017
The prevalence of diabetes for all age-groups worldwide was estimated to be 2.8% in 2000 and 4.4% in 2030. The total number of people with diabetes is projected to rise from 171 million in 2000 to 366 million in 2030. The prevalence of diabetes is higher in men than women, but there are more women with diabetes than men. The urban population in developing countries is projected to double between 2000 and 2030. The most important demographic change to diabetes prevalence across the world appears to be the increase in the proportion of people >65 years of age. These findings indicate that the “diabetes epidemic” will continue even if levels of obesity remain constant. Given the increasing prevalence of obesity, it is likely that these figures provide an underestimate of future diabetes prevalence.
The number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. The global prevalence of diabetes* among adults over 18 years of age has risen from 4.7% in 1980 to 8.5% in 2014. In 2012, an estimated 1.5 million deaths were directly caused by diabetes and another 2.2 million deaths were attributable to high blood glucose. Almost half of all deaths attributable to high blood glucose occur before the age of 70 years1. WHO projects that diabetes will be the 7th leading cause of death in 2030.
Diabetes Global 2017 will feature the latest developments in research, diagonosis and prevention and management of diabetes, new insulin analogues and new technologies and devices for diabetic prevention, and for treating obesity and many more. Not only will this innovative conference enhance your practical and theoretical knowledge, it will provide you with the unique opportunity to network with a wide range of professionals in the field of diabetes technologies and treatments.
The prevalence of diabetes as well as glucose intolerance is greater in men and in the regions of the Center and South of Italy. The prevalence of diabetes has doubled in Italy over the past decade and now affects about 3 million people. In Italy, the prevalence of diabetes is 6.6% among people over 20 years old, The Italian Ministry of Health estimates that the number of total undiagnosed cases of diabetes is approximately 2 million. By 2013, the number of cases of both type 1 and type 2 are expected to rise to about 2.7 million and 4 million, respectively. Current diabetes incidence ranges from 4 to 10 new cases per 100,000 inhabitants annually throughout most of the country, but is as high as 35 new cases per 100,000 in Sardinia. Approximately 15,000 new cases of type 1 diabetes and 185,000 new cases of type 2 diabetes are diagnosed nationwide each year, resulting in a and a type 1:type 2 ratio of 1:9. One recent study by the Associazione Medici Diabetologi (AMD, the Italian Association of Diabetes Doctors) found that the number of cases of both type 1 and type 2 diabetes is increasing at about 1% and 7-10% per year, likely due in part to improved screening measures and an increase in obesity and sedentary lifestyles. Reflecting this imperative Diabetes Global-2017 aims to educate pediatricians and achieve the goal of reducing infant mortality rate.
Societies Associated with Diabetes Research
FAND - Italian Association of Diabetics
Italian Association for the Defence of the Interests of Diabetics
Association of Diabetes
Association National Italian Diabetic Athletes
Italian Society of Diabetology
International Diabetes Federation- Italy
Primary Care Diabetes Society
Australian Diabetes Society
Emirates Diabetes Society
Society for Biomedical Diabetes Research
Immunology Of Diabetes Society
American Association of Diabetes Educators
American Diabetes Association
The Asian Association For The Study Of Diabetes
International Association of the Diabetes and Pregnancy Study Groups
Diabetes Association of Nigeria
Association of Children's Diabetes Clinicians
Canadian Diabetes Association
Market Value on Diabetic Research:
The impact of diabetes on the individual quality of life and general economy in Italy is substantial. Healthcare costs for patients with diabetes in Italy are estimated at approximately €5.5 billion annually, representing more than 6% of total national healthcare spending. The Cost of Diabetes in Europe—Type 2 Study(CODE-2), which measured the total healthcare costs for patients with type 2 diabetes in 8 European countries (Italy, Belgium, France, Germany, Netherlands, Spain, Sweden, and UK), found the total yearly (1998) costs for people with type 2 diabetes in Italy alone to be almost €5.2 billion, a per-patient expenditure of at least €2900. Among patients with type 2 diabetes in Italy examined by the CODE-2 study, 17.8% were hospitalized during the 6 month study, with an average hospital stay of 13 days. The cost of hospitalizations accounted for the greatest portion of total costs for all countries in the study, at 55%, leading non-antidiabetic drugs (21%), outpatient care (18%) and antidiabetic drugs (7%). Among non-antidiabetic drugs, the majority were cardiovascular and lipid-lowering (42%). Annual per-patient costs vary widely with primary treatment type, with the highest per-patient costs accrued by those treated with diet and exercise alone.
Market Growth of Diabetic Research in the Last and Upcoming Ten Years
With this enthusiastic support of our Organizing Committee and Editorial Board Member, we are overwhelmed to announce 16th Global Diabetes Conference & Medicare Expo (Diabetes Global 2017) as a continuum of our previous successful conference. Diabetes Global 2017 will be held in Rome, Italy during March 22-23, 2017. The conference will focus on Applying Science and Technology to Fight Diabetes.
This conference includes the renowned scientists, geneticist, microbiologists, doctors, professors, public health planners, physicians, dietitians, pharmacists, students under the research of diabetes, industrial delegates and those using bioinformatics tools for studying under the single roof to discuss and for improving the current therapies, and exploring radical new approaches. The event offers a best platform with its well organized scientific program to the audience which includes interactive panel discussions, keynote lectures, plenary talks and poster sessions, workshop, symposium etc.
For more details, please visit: http://globaldiabetes.conferenceseries.com/europe